The first patient has been dosed in a Phase 1/2 study of GB221, a next-generation gene therapy for SMA type 1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results